You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

brolucizumab,

Showing 1 - 25 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Safety and Effectiveness of Brolucizumab in Diabetic Macular

Not yet recruiting
  • Diabetic Macular Edema
  • brolucizumab
  • (no location specified)
Jul 17, 2023

Age-Related Macular Degeneration, Pachychoroid Neovasculopathy Trial (Brolucizumab Injection [Beovu])

Not yet recruiting
  • Age-Related Macular Degeneration
  • Pachychoroid Neovasculopathy
  • Brolucizumab Injection [Beovu]
  • (no location specified)
Dec 21, 2022

Patterns With Brolucizumab in Germany -Retrospective Cohort

Completed
  • Neovascular Age-related Macular Degeneration
    • Porto Salvo, Portugal
      Novartis
    Aug 28, 2023

    From Patients Treated With Brolucizumab in Post-marketing

    Completed
    • Intraocular Inflammation
    • Retinal Vascular Occlusion
    • Brolucizumab
    • Basel, Switzerland
      Novartis Investigative center
    Dec 19, 2022

    Brolucizumab in Pre-treated nAMD in the Real-world Setting

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Brolucizumab
    • (no location specified)
    Aug 8, 2022

    Early Real-world Evidence of Brolucizumab in Neovascular

    Completed
    • Neurovascular Age-related Macular Degeneration
      • Bangalore, India
      • +3 more
      Apr 26, 2023

      Wet Macular Degeneration Trial in Prague (Aflibercept 40 MG/ML [Eylea], Brolucizumab-Dbll 120 MG/ML [Beovu], Ranibizumab 6 MG/ML

      Withdrawn
      • Wet Macular Degeneration
      • Aflibercept 40 MG/ML [Eylea]
      • +2 more
      • Prague, Czechia
        Department of Ophthalmology, Faculty hospital Kralovske Vinohrad
      Aug 7, 2022

      Wet Age-related Macular Degeneration Trial in Bern (Aflibercept, Brolucizumab, early treat and extend (T&E))

      Enrolling by invitation
      • Wet Age-related Macular Degeneration
      • Bern, Switzerland
        Berner Augenklinik am Lindenhofspital
      May 13, 2022

      Macular Polypoidal Choroidal Vasculopathy (PCV) Trial in Korea, Republic of (Brolucizumab 6mg)

      Not yet recruiting
      • Macular Polypoidal Choroidal Vasculopathy (PCV)
      • Brolucizumab 6mg
      • Busan, Korea, Republic of
      • +13 more
      Dec 19, 2022

      Fluid Resolution and Effectiveness of Brolucizumab for nAMD in

      Recruiting
      • Neovascular Age-related Macular Degeneration (nAMD)
      • Funchal, Portugal
      • +11 more
      Jun 9, 2022

      Diabetic Macular Edema Trial in China (Brolucizumab, Aflibercept)

      Active, not recruiting
      • Diabetic Macular Edema
      • Guangzhou, Guangdong, China
      • +23 more
      Jan 20, 2023

      Neovascular Age-related Macular Degeneration Trial in Binningen (Brolucizumab 6 mg solution for intravitreal injection)

      Terminated
      • Neovascular Age-related Macular Degeneration
      • Brolucizumab 6 mg solution for intravitreal injection
      • Binningen, Baselland, Switzerland
        Vista Klinik
      Dec 8, 2021

      Neovascular Age-related Macular Degeneration

      Completed
      • Age-related Macular Degeneration (AMD)
      • East Hanover, New Jersey
        Novartis Investigative Site
      Dec 15, 2021

      Patients With nAMD in UK Routine Clinical Practice

      Recruiting
      • Neovascular Age-related Macular Degeneration
      • brolucizumab
      • Peterborough, Cambridgeshire, United Kingdom
      • +12 more
      Jul 18, 2022

      Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)

      Recruiting
      • Neovascular Age-Related Macular Degeneration
      • Brolucizumab 6mg
      • Aflibercept 2 mg
      • Guangzhou, Guangdong, China
      • +30 more
      Jan 20, 2023

      Neovascular Age-related Macular Degeneration

      Completed
      • Age-related Macular Degeneration (AMD)
      • East Hanover, New Jersey
        Novartis Pharmaceuticals
      Oct 19, 2021

      Age-Related Macular Degeneration Trial in Hong Kong (Brolucizumab, Aflibercept)

      Recruiting
      • Age-Related Macular Degeneration
      • Hong Kong, Hong Kong
        Grantham Hospital
      Jan 25, 2023

      Neovascular Age-related Macular Degeneration Trial in Italy (Brolucizumab)

      Recruiting
      • Neovascular Age-related Macular Degeneration
      • Ancona, AN, Italy
      • +18 more
      Aug 10, 2022

      Age-related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration Trial in Germany, Switzerland (Brolucizumab)

      Recruiting
      • Age-related Macular Degeneration
      • +5 more
      • Brolucizumab
      • Regensburg, Bavaria, Germany
      • +32 more
      Jan 20, 2023

      Age-related Macular Degeneration (AMD) Trial (brolucizumab)

      Withdrawn
      • Age-related Macular Degeneration (AMD)
      • (no location specified)
      Sep 21, 2021

      Neovascular Age Related Macular Degeneration Trial in France (RTH258/Brolucizumab)

      Active, not recruiting
      • Neovascular Age Related Macular Degeneration
      • Nice, Cedex1, France
      • +39 more
      Jan 20, 2023

      Neovascular Age-related Macular Degeneration Enrolled in

      Completed
      • Age-related Macular Degeneration (AMD)
      • All participants
      • East Hanover, New Jersey
        Novartis Investigative Site
      Oct 6, 2021

      Number of Patient Eyes That Remained on or Switched to Anti-VEGF

      Completed
      • Age-related Macular Degeneration (AMD)
      • East Hanover, New Jersey
        Novartis Investigational site
      Oct 6, 2021

      Regulatory Post-Marketing Surveillance Study for Brolucizumab

      Recruiting
      • Neovascular Age-related Macular Degeneration
      • brolucizumab
      • Daegu, Dalseo Gu, Korea, Republic of
      • +26 more
      Jun 21, 2022

      Beovu Experience UZ Leuven

      Active, not recruiting
      • Age-Related Macular Degeneration
      • Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution
      • Leuven, Belgium
        UZLEUVEN
      Jan 21, 2022